<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356014</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0206</org_study_id>
    <nct_id>NCT04356014</nct_id>
  </id_info>
  <brief_title>Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus</brief_title>
  <official_title>Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus : to a Form of Lichen Planus-like Lupus Erythematosus ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic
      lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare
      phenomenon seldom reported in literature. The investigators hypothesize that
      clinic-immunologic assessment and detailed investigation of cutaneous biopsy specimen of PPK
      and erythema of patients suffering from SLE and SCLE could lead to determine more precisely
      nosological settings of this injury. Report the different therapeutics with efficacy
      assessment could be helpful to highlight useful treatment for these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Context: Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during
      systemic lupus erythematosus (SLE) is a rare phenomenon seldom reported in literature. To our
      knowledge no case has been described in subacute cutaneous lupus erythematosus (SCLE) so far.
      Pathogeny and etiologic origin are not clear: it could be no-specific cutaneous manifestation
      of SLE, verrucous chilblain lupus, lichen planus, discoid lupus erythematosus lesions,
      overlap syndrome or coexistence of both diseases.

      Objective:

        1. Determine clinical immunological and histopathological features of patients with PPK and
           livid telangiectatic erythema-associated suffering from SLE and SCLE

        2. Describe the different therapeutics used and efficacy assessment Methods: Multicentric
           retrospective descriptive study reporting 14 patients with SLE or SCLE suffering from an
           acral livid erythematosus keratoderma, with clinical data regarding lupus erythematosus
           and acral keratoderma, immunological blood samples findings and histopathological
           results of keratoderma and livid erythema biopsies with direct immunofluorescence if
           performed. The treatments set down in order to heal are noted followed by efficacy
           assessment: total failure, partial remission, complete remission.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine clinic immunologic features</measure>
    <time_frame>1 day</time_frame>
    <description>Determine clinic immunologic features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine clinic histopathologic features</measure>
    <time_frame>1 day</time_frame>
    <description>Epidemiologic clinic immunologic histopathologic data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Different therapeutics used</measure>
    <time_frame>1 day</time_frame>
    <description>Describe the different therapeutics used. Report of the drug therapy used to heal acral keratoderma for each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Different therapeutics efficacy assessment</measure>
    <time_frame>1 day</time_frame>
    <description>Efficacy assessment of the treatments: total failure, partial remission, complete remission</description>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Lichen Planus</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      paraffin-embedded and frozen cuteaneous biopsy specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffering from SLE or SCLE with palmar and or plantar keratoderma with livid
        telangiectatic erythema
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  &gt; 18 years old

          -  suffering from SLE or SCLE according to 2019 ACR/EULAR criteria

          -  With palmar and or plantar keratoderma with livid telangiectatic erythema

        Exclusion criteria:

          -  &lt; 18 years old

          -  suffering from lupus lesions without SLE or SCLE criteria

          -  without palmar and or plantar keratoderma with livid telangiectatic erythema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier BESSIS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palmoplantar keratoderma with livid telangiectatic erythema</keyword>
  <keyword>Systemic lupus</keyword>
  <keyword>Subacute lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoderma, Palmoplantar</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

